遠展(00035.HK)奪市建局西營盤合作項目 中標價12.4億低市場預期
市建局公布,經過公開招標競投後,決定與遠東發展(00035.HK)全資附屬公司Mega Source Global Limited,合作發展西營盤崇慶里/桂香街發展項目。該公司以投標金額港幣12.4億元投得是次項目的合作發展合約。中標價低於市場估值介乎約12.6億元至16.1億元的下限。
市建局早前公開邀請發展商就本項目提交合作發展意向書,其後邀請34家符合要求的發展商,入標競投合作發展本項目,在2022年7月11日截標時,共接獲九份標書。
項目於2017年7月展開,地盤面積為1,077.3平方米。項目完成後,預計可提供約8,804平方米的總樓面面積。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.